The purpose of this study is to directly compare the safety and efficacy of intra-thrombus alfimeprase 0.3 mg/kg with placebo in acute peripheral arterial occlusion (PAO) as measured by a 30 day open vascular free surgery rate.
There is an unmet medical need to improve thrombolytic therapy in acute peripheral arterial occlusion (PAO). Currently used plasminogen activators can result in increased circulating levels of plasmin that result in a systemic "lytic state" that does not distinguish between physiologic and pathologic thrombosis. In general, mean plasminogen activator infusion durations of greater than 24 hours in order to achieve successful thrombolysis are problematic in a disease where delayed restoration of arterial flow can lead to irreversible ischemic damage. A direct thrombolytic agent like alfimeprase, with a rapid mechanism of action and a potentially safer bleeding risk profile, could facilitate a rapid restoration of arterial flow and avoidance of open vascular surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
300
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
30 day open vascular surgery free rate
Rate of arterial flow restoration at 4 hours after initiation of study drug
Rate of improvement in index limb ABI by >=0.15 at 30 days
Change in the severity of planned surgical procedures at 30 days
Change in index limb pain severity score at 30 days
30 day open vascular surgery free survival rate
Length of hospital stay
Length of intensive care unit (ICU) stay
Safety
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.